Advances in Lymphoma Research

  • Fernando Cabanillas
  • M. Alma Rodriguez

Part of the Cancer Treatment and Research book series (CTAR, volume 85)

Table of contents

  1. Front Matter
    Pages i-x
  2. New Therapeutic Advances

    1. Front Matter
      Pages 1-1
    2. Peter McLaughlin, Lester E. Robertson, Michael J. Keating
      Pages 3-14
    3. Alan Saven, Lawrence D. Piro
      Pages 15-26
  3. New Histopathologic Entities

    1. Front Matter
      Pages 27-27
    2. M. Alma Rodriguez, William C. Pugh
      Pages 41-50
  4. New Perspectives on Clinical Prognostic Parameters and Treatment

  5. New Biomolecular Markers/Targets

    1. Front Matter
      Pages 105-105
    2. Thomas P. Miller, Ellen M. Chase, William S. Dalton, Thomas M. Grogan
      Pages 107-117
    3. Philip T. Neff, Bradley W. McIntyre
      Pages 119-139
  6. Back Matter
    Pages 161-169

About this book


Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third­ generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results.


Grading cancer cell chemotherapy lymphoma oncology

Editors and affiliations

  • Fernando Cabanillas
    • 1
  • M. Alma Rodriguez
    • 1
  1. 1.Department of HematologyM.D. Anderson Cancer CenterHoustonUSA

Bibliographic information

  • DOI
  • Copyright Information Kluwer Academic Publishers 1996
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-6851-9
  • Online ISBN 978-1-4615-4129-5
  • Series Print ISSN 0927-3042
  • Buy this book on publisher's site